Rallybio Corp (RLYB)

Apr 01, 2025

Rallybio stock plunges to 52-week low, hitting $0.6 - Investing.com India

Apr 01, 2025

Apr 01, 2025

Rallybio stock plunges to 52-week low, hitting $0.6 By Investing.com - Investing.com Canada

Apr 01, 2025

Mar 24, 2025

Rallybio stock plunges to 52-week low at $0.62 amid market challenges - Investing.com Canada

Mar 24, 2025

Mar 24, 2025

Rallybio stock plunges to 52-week low at $0.62 amid market challenges By Investing.com - Investing.com South Africa

Mar 24, 2025

Mar 20, 2025

HC Wainwright Issues Positive Estimate for Rallybio Earnings - Defense World

Mar 20, 2025

Mar 18, 2025

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Mar 18, 2025

Mar 18, 2025

Rallybio (NASDAQ:RLYB) Receives “Buy” Rating from HC Wainwright - Defense World

Mar 18, 2025

Mar 17, 2025

Rallybio’s Promising Developments and Financial Stability Justify Buy Rating - TipRanks

Mar 17, 2025

Mar 15, 2025

Rallybio Corporation (NASDAQ:RLYB) Is Expected To Breakeven In The Near Future - Simply Wall St

Mar 15, 2025

Mar 14, 2025

Rallybio’s Promising Financial Stability and Strategic Clinical Advancements Drive Buy Rating - TipRanks

Mar 14, 2025

Mar 14, 2025

Rallybio Corporation Reports 2024 Financial Results and Progress - TipRanks

Mar 14, 2025

Mar 13, 2025

Rallybio revises common stock offering to $9.55 million By Investing.com - Investing.com Australia

Mar 13, 2025

Mar 13, 2025

Rallybio revises common stock offering to $9.55 million - Investing.com

Mar 13, 2025

Mar 13, 2025

Rallybio earnings beat by $0.55, revenue fell short of estimates - Investing.com UK

Mar 13, 2025

Mar 13, 2025

Rallybio Corp SEC 10-K Report - TradingView

Mar 13, 2025

Mar 13, 2025

Promising Developments and Financial Stability Support Buy Rating for Rallybio - TipRanks

Mar 13, 2025

Mar 13, 2025

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - BioSpace

Mar 13, 2025

Mar 13, 2025

Rallybio reports Q4 EPS (25c), consensus (30c) - TipRanks

Mar 13, 2025

Mar 11, 2025

Rallybio stock plunges to 52-week low of $0.66 By Investing.com - Investing.com Australia

Mar 11, 2025

Mar 11, 2025

Rallybio stock plunges to 52-week low of $0.66 - Investing.com

Mar 11, 2025

Mar 09, 2025

Rallybio (RLYB) to Release Quarterly Earnings on Tuesday - Defense World

Mar 09, 2025

Mar 04, 2025

Rallybio stock hits 52-week low at $0.68 amid market challenges - Investing.com Australia

Mar 04, 2025

Mar 03, 2025

Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans? - Yahoo Finance

Mar 03, 2025

Feb 27, 2025

New Haven-based biotech Rallybio faces delisting from Nasdaq - Hartford Business Journal

Feb 27, 2025

Feb 26, 2025

Rallybio faces Nasdaq delisting over share price woes - Investing.com India

Feb 26, 2025

Feb 25, 2025

Rallybio faces Nasdaq delisting over share price woes By Investing.com - Investing.com South Africa

Feb 25, 2025

Feb 25, 2025

Can Rallybio's Rare Disease Innovations Impress Investors at the TD Cowen Conference? - StockTitan

Feb 25, 2025

Feb 24, 2025

Rallybio stock plunges to 52-week low at $0.72 amid market challenges - Investing.com Nigeria

Feb 24, 2025

Feb 15, 2025

Rallybio doses first subject in Phase II trial of treatment for FNAIT in Europe - MSN

Feb 15, 2025

Feb 14, 2025

Rallybio (NASDAQ:RLYB) Earns Buy Rating from HC Wainwright - Defense World

Feb 14, 2025

Feb 13, 2025

Rallybio stock plunges to 52-week low of $0.73 amid market challenges - MSN

Feb 13, 2025

Feb 12, 2025

Rallybio begins Phase 2 trial for FNAIT prevention therapy - MSN

Feb 12, 2025

Feb 12, 2025

Rallybio begins Phase 2 trial for FNAIT prevention therapy By Investing.com - Investing.com Nigeria

Feb 12, 2025

Feb 12, 2025

Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial - BioSpace

Feb 12, 2025

Jan 22, 2025

Rallybio Co. (NASDAQ:RLYB) Receives Average Rating of “Moderate Buy” from Analysts - Defense World

Jan 22, 2025